Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Colorcon
McKesson
Mallinckrodt
Harvard Business School

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REVEFENACIN

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Revefenacin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02109172 A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 2 2014-04-01 This study evaluated the safety and efficacy of once and twice daily TD-4208 and placebo when administered using a jet nebulizer for 7 days in a cross-over design to patients with moderate to severe chronic obstructive pulmonary disease.
NCT02459080 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 3 2015-09-01 The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
NCT02512510 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 3 2015-09-01 The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
NCT02518139 A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Active, not recruiting Theravance Biopharma R & D, Inc. Phase 3 2015-09-01 The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
NCT02578082 Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment Completed Theravance Biopharma R & D, Inc. Phase 1/Phase 2 2015-12-01 This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal renal function or severe (eGFR <30 mL/min/1.73 m2) renal impairment to evaluate the effect of renal impairment on the pharmacokinetics (PK) of TD 4208.
NCT02581592 Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment Completed Theravance Biopharma R & D, Inc. Phase 1/Phase 2 2015-11-01 This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of TD-4208.
NCT02772159 TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects Completed Theravance Biopharma R & D, Inc. Phase 1 2015-06-01 The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD). The study drug will be tested in 6 healthy normal males. Dosing will include a single dose of study drug administered via an IV Infusion and an Oral Dose. There will be a 28 day washout period between each of the 2 dosing routes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Revefenacin

Condition Name

Condition Name for Revefenacin
Intervention Trials
Chronic Obstructive Pulmonary Disease (COPD) 5
Chronic Obstructive Pulmonary Disease 1
Renal Impairment 1
Cardiac Repolarization in Healthy Subjects 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Revefenacin
Intervention Trials
Pulmonary Disease, Chronic Obstructive 8
Lung Diseases, Obstructive 8
Lung Diseases 8
Respiratory Aspiration 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Revefenacin

Trials by Country

Trials by Country for Revefenacin
Location Trials
United States 10
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Revefenacin
Location Trials
South Carolina 3
Florida 2
Oregon 2
Arizona 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Revefenacin

Clinical Trial Phase

Clinical Trial Phase for Revefenacin
Clinical Trial Phase Trials
Phase 3 5
Phase 2 2
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Revefenacin
Clinical Trial Phase Trials
Completed 8
Active, not recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Revefenacin

Sponsor Name

Sponsor Name for Revefenacin
Sponsor Trials
Theravance Biopharma R & D, Inc. 10
Theravance Biopharma 1
Mylan Inc. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Revefenacin
Sponsor Trials
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Medtronic
Baxter
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.